艾米替诺福韦联合舒肝宁治疗慢性乙型病毒性肝炎的效果观察  

Efficacy observation of tenofovir amibufenamide combined with Shuganning in the treatment of chronic hepatitis B

作　　者：刘家燕 吕建林[2] 艾军[1] 戴铭[1] 张璐砾[1] 黄晶晶[2] 张文富[2] LIU Jiayan;LYU Jianlin;AI Jun;DAI Ming;ZHANG Luli;HUANG Jingjing;ZHANG Wenfu(Guangxi University of Chinese Medicine,Guangxi,Nanning 530299,China;The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi,Nanning 530023,China)

机构地区：[1]广西中医药大学,广西南宁530299 [2]广西中医药大学第一附属医院,广西南宁530023

出　　处：《中国医药科学》2024年第23期168-172,共5页China Medicine And Pharmacy

基　　金：[基金项目]中国博士后科学基金面上项目(2023MD734157);国家自然科学基金(81860839);桂派中医经典传承创新团队(2022B002);广西中医药大学“岐黄工程”高层次人才团队培育项目(202403);广西中医药大学第一附属医院青年拔尖人才项目(院党字[2022]48号)。

摘　　要：目的回顾性探讨艾米替诺福韦联合舒肝宁在慢性乙型病毒性肝炎治疗中的效果。方法选取2022年6月至2023年6月在广西中医药大学第一附属医院接受治疗的慢性乙型病毒性肝炎患者84例为研究对象,根据干预方式不同分为观察组和对照组,每组各42例。在给予常规药物和舒肝宁治疗的基础上,对照组予恩替卡韦,观察组则予艾米替诺福韦。观察两组治疗前后中医证候积分、血脂指标、肾功能、肝功能,以及治疗后的总体疗效、不良反应发生率。结果观察组的总有效率高于对照组。两组治疗前的中医证候积分、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、尿素氮(BUN)、血肌酐(SCr)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)比较,差异无统计学意义(P>0.05)。治疗后,两组的中医证候积分、ALT、AST、TBIL、BUN、SCr均降低,且观察组低于对照组(P<0.05)。在血脂方面,除TC外,两组TG、HDL-C、LDL-C差异均有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论在慢性乙型病毒性肝炎的治疗上,艾米替诺福韦与舒肝宁注射液联合用药,可以有效提高临床疗效,减少对肝肾功能的损害,在临床治疗中值得推广应用。Objective To retrospectively investigate the efficacy of tenofovir amibufenamide combined with Shuganning in the treatment of chronic hepatitis B.Methods A total of 84 patients with chronic hepatitis B treated in the First Affiliated Hospital of Guangxi University of Chinese Medicine from June 2022 to June 2023 were selected for the study.They were divided into the observation group and the control group according to different intervention methods,each with 42 patients.On the basis of conventional drugs and Shuganning,the control group was given entecavir and the observation group was given tenofovir amibufenamide.The traditional Chinese medicine syndrome score,blood lipid indexes,renal function,and liver function before and after treatment,and the overall efficacy and incidence of adverse reactions after treatment were observed.Results The total effective rate was higher in the observation group than that in the control group.There was no statistically significant difference between the two groups in the traditional Chinese medicine syndrome score,alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),blood urea nitrogen(BUN),serum creatinine(SCr),triglyceride(TG),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),and low-density lipoprotein cholesterol(LDL-C)before treatment(P>0.05).After treatment,The traditional Chinese medicine syndrome scores,ALT,AST,TBIL,BUN,and SCr of both groups decreased,and the observation group was lower than the control group(P<0.05).In terms of blood lipids,in addition to TC,the differences in TG,HDL-C,and LDL-C between the two groups were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of chronic hepatitis B,the combination of tenofovir amibufenamide and Shuganning Injection can effectively improve the clinical efficacy and reduce the damage to liver and renal function,which is worthy of promotion and

关 键 词：艾米替诺福韦 慢性乙型病毒性肝炎 中西医治疗 舒肝宁注射液 

分 类 号：R512.62[医药卫生—内科学]